Related Experiment Video
Updated: Jul 17, 2025
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
251
Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET.
Joseph Therriault1,2, Firoza Z Lussier1,2,3, Cécile Tissot1,2
1Translational Neuroimaging Laboratory Douglas Mental Health Institute McGill University Research Centre for Studies in Aging Montreal Quebec Canada.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|August 30, 2023
Summary
This study shows that amyloid beta (Aβ) accumulation, measured by [18F]AZD4694, increases over time, especially in individuals with existing Aβ pathology. This PET tracer can monitor Aβ levels in clinical trials and settings.
Area of Science:
- Neuroimaging
- Alzheimer's Disease Research
- Biomarker Development
Background:
- [18F]AZD4694 is an established amyloid beta (Aβ) imaging agent.
- Longitudinal Aβ accumulation data using [18F]AZD4694 has been lacking.
- Understanding Aβ dynamics is crucial for Alzheimer's disease research.
Purpose of the Study:
- To assess longitudinal Aβ accumulation using [18F]AZD4694.
- To quantify annual rates of change in Aβ deposition.
- To evaluate the utility of [18F]AZD4694 in tracking disease progression.
Main Methods:
- 146 individuals underwent [18F]AZD4694 PET imaging at baseline and 2-year follow-up.
- Annual rates of [18F]AZD4694 standardized uptake value ratio (SUVR) change were calculated.
- Participants were stratified into clinically defined and biomarker-defined groups.
Main Results:
- Cognitively unimpaired older adults showed subtle [18F]AZD4694 SUVR increases.
- Aβ-positive cognitively unimpaired individuals exhibited higher annual [18F]AZD4694 SUVR increases.
- Aβ-positive mild cognitive impairment and dementia showed modest neocortical [18F]AZD4694 SUVR accumulation.
Conclusions:
- [18F]AZD4694 PET can track longitudinal Aβ accumulation.
- Higher baseline Aβ burden correlates with greater [18F]AZD4694 SUVR increases.
- [18F]AZD4694 is valuable for monitoring Aβ in clinical trials and settings, especially before anti-amyloid therapies.
